Cumberland Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Mar 9, 2018 and accepted by EDGAR at Mar 9, 2018, 16:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2017-01-01 to 2017-12-31 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-10-01 to 2017-12-31 | −$903.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2017-01-01 to 2017-12-31 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $92.9k | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | $4.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | −$800.5k | us-gaap:NetIncomeLoss |
| Net income | 12 months2017-01-01 to 2017-12-31 | −$8.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | −$0.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-10-01 to 2017-12-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | −$0.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 15,911,577 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | −$557.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $276.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $3.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $45.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $68.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $93.2m | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $17.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $29.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-12-31 | $64.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-18-003034. Last ingested by Listed: Nov 11, 2026, 03:05 ET. Listed shows no prices and gives no investment advice.